-- Announced nomination of OKI-355, a next-generation PI3Kα pan-mutant selective inhibitor candidate, in vascular anomalies -- Initiated a discovery research program to expand the company’s pipeline...
-- Financing led by Access Biotechnology with participation from new and existing investors -- Financing to support advancement of two next-generation PI3K α pan-mutant inhibitors for breast cancer...
-- Data from the ongoing PIKture-01 trial is expected to be announced in March 2026 ; continued enrollment in breast cancer triplet combinations -- Next-generation PI3K α pan-mutant inhibitor...
-- First patients dosed in triplet expansion arms of the PIKture-01 trial evaluating OKI-219 in combination with fulvestrant and ribociclib, and in combination with trastuzumab and tucatinib in patients...
BOULDER, Colo., Nov. 04, 2025 (GLOBE NEWSWIRE) -- OnKure Therapeutics, Inc. (Nasdaq: OKUR), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines, today announced...
-- PIKture-01, a phase 1 clinical trial assessing OKI-219 in patients with advanced solid tumors, including breast cancer, is on track for single agent and fulvestrant combination data in Q4 2025 ...
OKI-219 shows promising safety, tolerability, and pharmacokinetics, supporting further trials with fulvestrant in breast cancer patients.Quiver AI SummaryOnKure Therapeutics announced positive preliminary...